Belépés

NCT04670887Toborzás még nem indult

Comparison of Surgery and Active Surveillance in the Treatment of Bosniak III Renal Cysts

A Prospective Multicenter Trial Comparing Surgery Versus Active Surveillance In Patients With Bosniak 3 Renal Cystic Masses, A NoRenCa And FinnKidney Study

Forrás: ClinicalTrials.gov · Utoljára frissítve: 2021. febr. 17. · Több mint 12 hónapja nem frissült - kérdezd meg a helyszínt, nyitott-e még

Rövid összefoglaló (regiszter, angolul)

The incidence of renal cysts is rising due to increased abdominal imaging. Renal complicated cysts have been traditionally classified according to the Bosniak classification, which distinguishes cystic masses by specific features of walls and septa. The categories I and II are benign and class IIF most probably benign but needs a short radiological follow-up. Categories III and IV have been traditionally operated due to the increased risk of renal cell carcinoma. However, recently published studies show that approximately 50% of the operated Bosniak III cystic masses are benign, which means that half of the cases are overtreated by surgery. It has also been shown that surgical pathology of stable Bosniak IIF cysts is malignant in less than 1%, while the cysts, which are upgraded to higher Bosniak classes will show malignant surgical pathology in 85%. So far, there is lack of prospective data on active surveillance in Bosniak III cystic masses. The aim of the study is to compare active surveillance and surgery in patients with Bosniak III renal cystic masses. Patients will be randomized in active surveillance or immediate surgical excision of a cystic mass. In the active surveillance group, patients are followed according to the study protocol for 10 years and treated with delayed surgery if the cystic mass upgrades into Bosniak IV/solid, becomes symptomatic or grows over a preclassified threshold. The primary objective is to compare surgical pathology between patients treated with immediate surgery versus delayed surgery. According to recent retrospective data, active surveillance of Bosniak III cystic masses is reasonable and oncologically safe. Therefore a prospective randomized controlled trial is needed to get high level evidence to support a change in the treatment strategy. The study may significantly reduce unnecessary operations performed in patients with Bosniak III cystic masses.

Állapot (regiszter)
Toborzás még nem indult
Vizsgálattípus
Beavatkozással járó
Résztvevők száma
200 (tervezett)
Első benyújtás
2020. nov. 26.
Kezdés
2021. márc. 15.
Elsődleges befejezés
2024. jan. 11.
Fő szponzor
Helsinki University Central Hospital
Betegségek
Vesedaganat
NCT-szám
NCT04670887

Mit vállalsz

  • Vizsgálat típusa: Beavatkozással járó
  • Tervezett résztvevők: 200
  • 2021. márc. 15. és az elsődleges befejezés (2024. jan. 11.) között
  • Nincs megadott helyszín, ország nélkül
  • Vizitek és vizsgálatok: kérdezd a vizsgálat csapatát, a regiszter nem sorolja fel őket

A(z) ClinicalTrials.gov regisztermezőiből összeállítva. A vizsgálat felépítését írja le.

Ki nem vehet részt

Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.

Korábbi kezelés

  • Previously or simultaneously diagnosed and pathologically verified RCC
  • Previously or simultaneously radiographically identified solid mass or CM of Bosniak 3/4 with diameter ≥10mm

Más betegség

  • Genetic syndromes associated with RCC
  • Presence of radiographic findings which are suspect for nodal or distant metastatic disease

Laborértékek

  • Kidney insufficiency (GFR\<55 ml/min/1,73m2)

Egyéb

  • The target CM of Bosniak 3 has progressed in sequential imaging from Bosniak 1-2F
  • Symptomatic CM
  • Patients who have contraindications for both CT and MRI imaging. . Anatomically solitary kidney

Kiket keres a vizsgálat

  • A sporadic single CM of Bosniak 3 according to the Bosniak Classification v.2019 is diagnosed with CT or MRI
  • Maximal diameter of CM 10-70 mm
  • Age ≥50 years
  • ECOG performance status \<2
  • Life expectancy ≥5 years
  • Patient is fit to undergo surgery and AS.
  • Patient understands a national language or English
  • Signed informed consent

Életkor a regiszterben: 50 év – 75 év · Nem: nők és férfiak · Egészséges önkénteseket nem fogad

A teljes feltétellista: ClinicalTrials.gov

Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.